DrugId:  1
1. Name:  Cabozantinib
2. Groups:  Approved, Investigational
3. Description:  Cabozantinib was approved in 2012 and is a non-specific tyrosine kinase inhibitor. It is marketed as Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. It's label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. The FDA approved cabozantinib as Cabometyx for patients with advanced renal cell carcinoma in April 2016.
4. Indication:  For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
DrugId:  2
1. Name:  Tazemetostat
2. Groups:  Investigational
3. Description:  Tazemetostat has been used in trials studying the treatment of Rhabdoid Tumors, Synovial Sarcoma, Epithelioid sarcoma, INI1-negative Tumors, and Renal Medullary Carcinoma, among others.
4. Indication:  Not Available
DrugId:  3
1. Name:  Dulaglutide
2. Groups:  Approved, Investigational
3. Description:  Dulaglutide is a novel glucagon-like peptide-1 agonist (GLP-1) biologic drug consisting of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. Dulaglutide is indicated in the treatment of type 2 diabetes and can be used once a week. It was approved by the FDA in September 2014. Dulaglutide is manufactured and marketed by Eli Lily under the brand Trulicity™. It is not known if dulaglutide can increase the risk of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and is thus not recommended for use in populations with a personal or family history of these conditions. 
4. Indication:  Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DrugId:  4
1. Name:  Rovalpituzumab Tesirine
2. Groups:  Investigational
3. Description:  Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
4. Indication:  Not Available
DrugId:  5
1. Name:  Platinum
2. Groups:  Investigational
3. Description:  Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
4. Indication:  Not Available
DrugId:  6
1. Name:  Naptumomab Estafenatox
2. Groups:  Investigational
3. Description:  Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
4. Indication:  Not Available
DrugId:  7
1. Name:  Entolimod
2. Groups:  Investigational
3. Description:  Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  Lapachone
2. Groups:  Investigational
3. Description:  Lapachone has been used in trials studying the treatment of Cancer, Carcinoma, Advanced Solid Tumors, Head and Neck Neoplasms, and Carcinoma, Squamous Cell.
4. Indication:  Not Available
DrugId:  9
1. Name:  Lobaplatin
2. Groups:  Investigational
3. Description:  Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
4. Indication:  Not Available
DrugId:  10
1. Name:  Endostar
2. Groups:  Investigational
3. Description:  Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
4. Indication:  Not Available
DrugId:  11
1. Name:  Indusatumab vedotin
2. Groups:  Investigational
3. Description:  Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
4. Indication:  Not Available
DrugId:  12
1. Name:  Monalizumab
2. Groups:  Investigational
3. Description:  Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
4. Indication:  Not Available
DrugId:  13
1. Name:  EHC18
2. Groups:  Investigational
3. Description:  EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.
4. Indication:  Investigated for use/treatment in hepatitis (viral, C) and hepatocellular carcinoma.
DrugId:  14
1. Name:  Volociximab
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
DrugId:  15
1. Name:  Dusigitumab
2. Groups:  Investigational
3. Description:  Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
4. Indication:  Not Available
DrugId:  16
1. Name:  Ascrinvacumab
2. Groups:  Investigational
3. Description:  Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
4. Indication:  Not Available
DrugId:  17
1. Name:  Tecemotide
2. Groups:  Investigational
3. Description:  Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
4. Indication:  Not Available
DrugId:  18
1. Name:  Brontictuzumab
2. Groups:  Investigational
3. Description:  Brontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.
4. Indication:  Not Available
DrugId:  19
1. Name:  VPM4001
2. Groups:  Investigational
3. Description:  VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ). Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.
4. Indication:  Investigated for use/treatment in prostate cancer.
DrugId:  20
1. Name:  Lorvotuzumab mertansine
2. Groups:  Investigational
3. Description:  Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
4. Indication:  Not Available
DrugId:  21
1. Name:  Pipazethate
2. Groups:  Approved
3. Description:  A non-narcotic oral antitussive agent.
4. Indication:  For the treatment of cough.
DrugId:  22
1. Name:  Biomed 101
2. Groups:  Investigational
3. Description:  Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
4. Indication:  Investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma.
DrugId:  23
1. Name:  Bacillus calmette-guerin substrain connaught live antigen
2. Groups:  Approved, Investigational
3. Description:  Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.
4. Indication:  Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). 
DrugId:  24
1. Name:  Emibetuzumab
2. Groups:  Investigational
3. Description:  Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
4. Indication:  Not Available
DrugId:  25
1. Name:  Diethylnorspermine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in renal cell carcinoma, pancreatic cancer, melanoma, and lung cancer.
